文献速递肝病消化道肿瘤与早癌

程序性细胞死亡蛋白-1(PD-1)靶向免疫治疗在晚期肝细胞癌中的疗效与安全性:来自国际多中心真实世界队列的数据

Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort.
PubMed 文献 · Aliment Pharmacol Ther · 2019-04-12

这项回顾性国际多中心真实世界队列分析了65例晚期肝细胞癌患者,分别接受纳武利尤单抗(n=34)或帕博利珠单抗(n=31)治疗。总体缓解率12%、疾病控制率49%,中位至进展时间5.5个月、中位无进展生存期4.6个月、中位总生存期11.0个月;Child-Pugh B患者中位总生存期较A患者短(16.7 vs 8.6个月;P=0.065)。

要点

  • 纳武利尤单抗或帕博利珠单抗在晚期肝细胞癌中显示有前景的疗效与安全性。
  • 总体缓解率12%、疾病控制率49%,中位总生存期11.0个月。
  • Child-Pugh B患者中位总生存期较A患者短(16.7 vs 8.6个月;P=0.065)。

核心结论

  • 程序性细胞死亡蛋白-1靶向免疫治疗(纳武利尤单抗或帕博利珠单抗)在晚期肝细胞癌患者中显示出有前景的疗效和安全性,包括Child-Pugh B期和接受密集预处理的患者。

研究设计与样本

  • 回顾性分析了2015年7月10日至2018年12月31日(数据截止)在奥地利和德国六家中心接受纳武利尤单抗(n=34)或帕博利珠单抗(n=31)治疗的65例晚期肝细胞癌患者。

主要发现

  • Child-Pugh A/B/C级分别为32例(49%)、28例(43%)、5例(8%)。
  • 免疫治疗作为系统一线/二线/三线/四线治疗分别为9例(14%)、27例(42%)、26例(40%)、3例(5%)。
  • 54例患者至少有一次随访影像可评估影像学缓解,总体缓解率和疾病控制率分别为12%和49%。
  • 52例可评估患者中4例(8%)出现超进展疾病。
  • 中位至进展时间为5.5个月(95%CI 3.5-7.4),中位无进展生存期为4.6个月(95%CI 3.0-6.2),中位总生存期为11.0个月(95%CI 8.2-13.8)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Programmed cell death protein-1-targeted immunotherapy has shown promising results in phase II studies of hepatocellular carcinoma. AIM: To evaluate safety and efficacy of nivolumab and pembrolizumab in an international, multicentre, real-world cohort of patients with advanced hepatocellular carcinoma. METHODS: Sixty-five patients treated with nivolumab (n = 34) or pembrolizumab (n = 31) between July 10, 2015 and December 31, 2018 (data cut-off) across six centres in Austria and Germany were retrospectively analysed. RESULTS: Child-Pugh class A/B/C was 32 (49%)/28 (43%)/5 (8%). Immunotherapy was used as systemic first-/second-/third-/fourth-line treatment in 9 (14%)/27 (42%)/26 (40%)/3 (5%) patients. Fifty-four patients had at least one follow-up imaging and were, therefore, available for radiological response assessment. The overall response and disease control rates were 12% and 49% respectively. Of 52 evaluable patients, four (8%) had hyperprogressive disease. Median time to progression was 5.5 (95% CI, 3.5-7.4) months, median progression-free survival was 4.6 (95% CI, 3.0-6.2) months, and median overall survival was 11.0 (95% CI, 8.2-13.8) months. Most common adverse events were infections (n = 7), rash (n = 6), pruritus (n = 3), fatigue (n = 3), diarrhoea (n = 3) and hepatitis (n = 3). Efficacy and safety results were comparable between Child-Pugh A and B patients; however, median overall survival (OS) was shorter in Child-Pugh B patients (16.7 vs 8.6 months; P = 0.065). There was no difference in terms of efficacy and adverse events between patients who received immunotherapy as first-/second-line and third-/fourth-line respectively. CONCLUSIONS: Programmed cell death protein-1-targeted immunotherapy with nivolumab or pembrolizumab showed promising efficacy and safety in patients with advanced hepatocellular carcinoma, including subjects with Child-Pugh stage B and patients with intensive pretreatment.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Scheiner B, Kirstein MM, Hucke F, et al. Programmed cell death protein-1 (PD-1)-targeted immunotherapy in advanced hepatocellular carcinoma: efficacy and safety data from an international multicentre real-world cohort. Aliment Pharmacol Ther. 2019. PMID: 30980420. doi:10.1111/apt.15245

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。